Fresenius Kabi announced it has received approval from the Food and Drug Administration (FDA) to market Neostigmine Methylsulfate Injection, the generic version of Eclat’s Bloxiverz.
Neostigmine Methylsulfate is a cholinesterase inhibitor indicated to reverse the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery. Neostigmine Methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade.
Neostigmine Methylsulfate Injection is expected to launch later this year.
For more information call (888) 386-1300 or visit Fresenius-Kabi.com.